Director, Global Commercial Leader, Early Heme Pipeline

**General Description:**. BeOne, a global oncology company, has produced a robust pipeline of New Molecular Entities (NMEs) with potential to change the standard of care across numerous disease areas. More than 10 additional NMEs can be expected from the Discovery organization in 2026, adding to an already comprehensive set of molecules spanning multiple modalities and which are currently in early